Myasthenia gravis (MG) is an autoimmune disorder of neuromuscular transmission. MG pathology is attributed to the presence of acetylcholine receptor (AChR) autoantibodies, which target the AChR at the neuromuscular junction. Many patients remain medically refractory or have intolerable adverse effects to current therapies; thus, another agent for the management of MG is needed. Several recent studies, including one performed by our group, have demonstrated the benefits of B cell depletion via rituximab treatment in MG patients. The NINDS-NeuroNEXT is conducting a multicenter randomized, double blind, placebo controlled Phase II clinical trial evaluating whether rituximab is a safe and beneficial therapeutic for MG. We have partnered with this trial so that we can improve the understanding of the mechanism of action of B cell depletion in MG and so that fundamental questions regarding human autoimmunity can be addressed. Specimens prior to, during and after treatment will be collected for our work. This study presents a unique opportunity to study both drug and disease mechanisms because unlike many other autoimmune diseases in which rituximab has been used, MG affords the investigation of antigen-specific components that directly participate in the immunopathology of the disease. Our mechanistic studies will test the hypothesis that the mechanism underlying clinical benefit involves a reservoir of autoreactive memory B cells that supply a population of antibody secreting cells and is critical to MG autoantibody production. Rituximab eliminates this reservoir of memory B cells~ then the newly formed B cell compartment is reshaped such that autoantibody production is diminished. To test this hypothesis, we have developed/applied assays to measure B cell tolerance defects, the repertoire of the B cell compartments and the B cell subsets that produce MG autoantibodies. This work will further our understanding of MG immunopathology and it represents the first step toward gaining a more complete understanding of the immune mechanisms underlying the treatment of B cell-mediated autoimmune diseases with rituximab. This proposal is directly relevant to the human disease and is in clear alignment and relevance to the mission of the NIH. That is, this translational research focuses on studying the human disease with human-derived cells. Innovative, novel technology such as next generation sequencing will be applied to answer fundamental questions. The study is designed to elucidate the pathogenic role of a major immunological component in MG that is the contribution of B cells, including an investigation of fundamental autoimmune mechanisms, namely B cell tolerance. Through studying MG cell-mediated immunology we will further define the events that both initiate and propagate this disease that will provide Fundamental insight into the mechanisms of autoimmune disease.
Myasthenia gravis (MG) is a chronic, disabling autoimmune neurological disease for which current treatments are ineffective in many patients. We will perform a mechanistic study linked to a clinical trial that will determine whether B cell depletion affected by the drug rituximab, is an effective treatment for MG. The mechanistic study will define the immunological events that both initiate and propagate this disease, thereby providing fundamental insight into the mechanisms of MG pathology and how the treatment affects clinical improvement.
| Cao, Yonghao; Amezquita, Robert A; Kleinstein, Steven H et al. (2016) Autoreactive T Cells from Patients with Myasthenia Gravis Are Characterized by Elevated IL-17, IFN-?, and GM-CSF and Diminished IL-10 Production. J Immunol 196:2075-84 |
